BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1703 related articles for article (PubMed ID: 29743717)

  • 1. Integrating oncolytic viruses in combination cancer immunotherapy.
    Bommareddy PK; Shettigar M; Kaufman HL
    Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of oncolytic virus immunotherapies to subvert cancer immune evasion.
    Workenhe ST; Verschoor ML; Mossman KL
    Future Oncol; 2015; 11(4):675-89. PubMed ID: 25686121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies.
    van Vloten JP; Workenhe ST; Wootton SK; Mossman KL; Bridle BW
    J Immunol; 2018 Jan; 200(2):450-458. PubMed ID: 29311387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
    Zhang B; Cheng P
    Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulation in Oncolytic Measles Virotherapy.
    Dietz L; Engeland CE
    Methods Mol Biol; 2020; 2058():111-126. PubMed ID: 31486034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy.
    Shin DH; Nguyen T; Ozpolat B; Lang F; Alonso M; Gomez-Manzano C; Fueyo J
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Viruses: Therapeutics With an Identity Crisis.
    Breitbach CJ; Lichty BD; Bell JC
    EBioMedicine; 2016 Jul; 9():31-36. PubMed ID: 27407036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newcastle disease virus: a promising agent for tumour immunotherapy.
    Zhao L; Liu H
    Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.
    Achard C; Surendran A; Wedge ME; Ungerechts G; Bell J; Ilkow CS
    EBioMedicine; 2018 May; 31():17-24. PubMed ID: 29724655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Circuits of Immune Sensing and Response to Oncolytic Virotherapy.
    Bhatt DK; Daemen T
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR; Vile RG
    Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of NK cells in immunotherapy and virotherapy of solid tumors.
    Cantoni C; Grauwet K; Pietra G; Parodi M; Mingari MC; De Maria A; Favoreel H; Vitale M
    Immunotherapy; 2015; 7(8):861-82. PubMed ID: 26314197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic Virotherapy and the Tumor Microenvironment.
    Berkey SE; Thorne SH; Bartlett DL
    Adv Exp Med Biol; 2017; 1036():157-172. PubMed ID: 29275471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.